More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$446607741
EPS
-0.1
P/E ratio
--
Price to sales
1.58
Dividend yield
--
Beta
1.815256
Previous close
$6.77
Today's open
$6.70
Day's range
$6.45 - $6.83
52 week range
$6.33 - $14.51
show more
CEO
Randy Teel
Employees
246
Headquarters
New Haven, CT
Exchange
Nasdaq Global Select
Shares outstanding
65485006
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Arvinas to Present at Jefferies Global Healthcare Conference
NEW HAVEN, Conn., Nov. 11, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, November 18 at 9:00 a.m. GMT/4:00 a.m. EST.
GlobeNewsWire • Nov 11, 2026

Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH®) Annual Meeting
– Data presentation to include safety, pharmacokinetics (PK), and pharmacodynamics (PD) from all patients, with preliminary efficacy from patients with T-cell lymphomas, in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) – NEW HAVEN, Conn., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that preliminary clinical data from the Phase 1 study of ARV-393 (zaloblideg) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) will be presented at the 2026 American Society of Hematology (ASH®) Annual Meeting, taking place December 12- 15, 2026, in New Orleans, Louisiana.
GlobeNewsWire • Nov 4, 2026

What Arvinas (ARVN) Said on Its Q3 Earnings Call
Arvinas NASDAQ: ARVN outlined upcoming clinical milestones across its oncology and neurology pipeline during its third-quarter 2026 earnings call, while reporting lower operating expenses and a cash runway projected into the second half of 2028.
MarketBeat • Nov 3, 2026

Arvinas, Inc. (ARVN) Q3 2026 Earnings Call Transcript
Arvinas, Inc. (ARVN) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 3, 2026

Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update
– Initiated dosing in a Phase 1/2 trial of ARV-6723, an immuno-oncology oral PROTAC designed to degrade HPK1, a negative regulator of immune activation – – Reaffirmed commitment to share clinical data from three Phase 1 programs - ARV-393, ARV-027 and ARV-6723 - in 4Q 2026 and 2027 – – Demonstrated novel oculomotor and biomarker movement with ARV-102 Phase 1 clinical data in patients with Parkinson's disease with oral presentation at MDS conference – – Company to host conference call today at 8:00 a.m. ET – NEW HAVEN, Conn.
GlobeNewsWire • Nov 3, 2026

Arvinas, Inc. (ARVN) Reports Q3 Loss, Misses Revenue Estimates
Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.8. This compares to a loss of $0.48 per share a year ago.
Zacks Investment Research • Nov 3, 2026

Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026
NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review third quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, November 3, 2026 at 8:00 a.m. ET.
GlobeNewsWire • Oct 27, 2026

Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation
– $25,000 monetary award to recognize an emerging researcher or research team advancing targeted protein degradation – – Nominations open November 1, 2026, and close December 31, 2026; winner to be recognized in mid-2027 – NEW HAVEN, Conn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the return of the Arvinas Early Career Researcher Award, which recognizes the research of an emerging researcher or research team bringing innovation, new approaches and creative thinking to the field of targeted protein degradation (TPD).
GlobeNewsWire • Oct 27, 2026

Reasons Why Investors Should Consider Betting on Arvinas Stock
ARVN's first FDA-approved PROTAC degrader validates its technology, while a diverse pipeline targeting cancer and neurological disorders offers further growth potential.
Zacks Investment Research • Oct 13, 2026

Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson's Disease
– Data showed improvements in an objective measure of impaired eye movement associated with Parkinson's disease, with a correlation between reductions in LRRK2 cerebrospinal fluid (CSF) biomarkers to these changes in oculomotor function and changes in synaptic biomarkers –
GlobeNewsWire • Oct 7, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Arvinas Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.